Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed
The recent pandemic of COVID-19 has already infected millions of individuals and has resulted in the death of hundreds of thousands worldwide. Based on clinical features, pathology, and the pathogenesis of respiratory disorders induced by this and other highly homogenous coronaviruses, the evidence...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Nutrients |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6643/12/9/2561 |
_version_ | 1797555854001569792 |
---|---|
author | Konrad Kleszczyński Andrzej T. Slominski Kerstin Steinbrink Russel J. Reiter |
author_facet | Konrad Kleszczyński Andrzej T. Slominski Kerstin Steinbrink Russel J. Reiter |
author_sort | Konrad Kleszczyński |
collection | DOAJ |
description | The recent pandemic of COVID-19 has already infected millions of individuals and has resulted in the death of hundreds of thousands worldwide. Based on clinical features, pathology, and the pathogenesis of respiratory disorders induced by this and other highly homogenous coronaviruses, the evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response contribute to COVID-19 pathology; these are caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This leads to a cytokine storm and subsequent progression triggering acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), and often death. We and others have reported melatonin to be an anti-inflammatory and anti-oxidative molecule with a high safety profile. It is effective in critical care patients by reducing their vascular permeability and anxiety, inducing sedation, and improving their quality of sleep. As melatonin shows no harmful adverse effects in humans, it is imperative to introduce this indoleamine into clinical trials where it might be beneficial for better clinical outcomes as an adjuvant treatment of COVID-19-infected patients. Herein, we strongly encourage health care professionals to test the potential of melatonin for targeting the COVID-19 pandemic. This is urgent, since there is no reliable treatment for this devastating disease. |
first_indexed | 2024-03-10T16:54:36Z |
format | Article |
id | doaj.art-10273af1d46f4f80b6ff5b58b1a271ff |
institution | Directory Open Access Journal |
issn | 2072-6643 |
language | English |
last_indexed | 2024-03-10T16:54:36Z |
publishDate | 2020-08-01 |
publisher | MDPI AG |
record_format | Article |
series | Nutrients |
spelling | doaj.art-10273af1d46f4f80b6ff5b58b1a271ff2023-11-20T11:10:57ZengMDPI AGNutrients2072-66432020-08-01129256110.3390/nu12092561Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently NeededKonrad Kleszczyński0Andrzej T. Slominski1Kerstin Steinbrink2Russel J. Reiter3Department of Dermatology, University of Münster, Von-Esmarch-Str. 58, 48149 Münster, GermanyDepartment of Dermatology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USADepartment of Dermatology, University of Münster, Von-Esmarch-Str. 58, 48149 Münster, GermanyDepartment of Cellular and Structural Biology, UT Health, San Antonio, TX 78229, USAThe recent pandemic of COVID-19 has already infected millions of individuals and has resulted in the death of hundreds of thousands worldwide. Based on clinical features, pathology, and the pathogenesis of respiratory disorders induced by this and other highly homogenous coronaviruses, the evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response contribute to COVID-19 pathology; these are caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This leads to a cytokine storm and subsequent progression triggering acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), and often death. We and others have reported melatonin to be an anti-inflammatory and anti-oxidative molecule with a high safety profile. It is effective in critical care patients by reducing their vascular permeability and anxiety, inducing sedation, and improving their quality of sleep. As melatonin shows no harmful adverse effects in humans, it is imperative to introduce this indoleamine into clinical trials where it might be beneficial for better clinical outcomes as an adjuvant treatment of COVID-19-infected patients. Herein, we strongly encourage health care professionals to test the potential of melatonin for targeting the COVID-19 pandemic. This is urgent, since there is no reliable treatment for this devastating disease.https://www.mdpi.com/2072-6643/12/9/2561melatoninCOVID-19inflammationimmune responseclinical trials |
spellingShingle | Konrad Kleszczyński Andrzej T. Slominski Kerstin Steinbrink Russel J. Reiter Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed Nutrients melatonin COVID-19 inflammation immune response clinical trials |
title | Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed |
title_full | Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed |
title_fullStr | Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed |
title_full_unstemmed | Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed |
title_short | Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed |
title_sort | clinical trials for use of melatonin to fight against covid 19 are urgently needed |
topic | melatonin COVID-19 inflammation immune response clinical trials |
url | https://www.mdpi.com/2072-6643/12/9/2561 |
work_keys_str_mv | AT konradkleszczynski clinicaltrialsforuseofmelatonintofightagainstcovid19areurgentlyneeded AT andrzejtslominski clinicaltrialsforuseofmelatonintofightagainstcovid19areurgentlyneeded AT kerstinsteinbrink clinicaltrialsforuseofmelatonintofightagainstcovid19areurgentlyneeded AT russeljreiter clinicaltrialsforuseofmelatonintofightagainstcovid19areurgentlyneeded |